Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation-Reference-Cited by-同舟云学术

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation

Published:2020-04-14 Issue:9 Volume:55 Page:1810-1816
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Costa Luciano J.^ORCID,Iacobelli Simona,Pasquini Marcelo C.,Modi Riddhi,Giaccone Luisa,Blade Joan,Schonland Stefan,Evangelista Andrea,Perez-Simon Jose A.,Hari Parameswaran,Brown Elizabeth E.,Giralt Sergio A.,Patriarca Francesca,Stadtmauer Edward A.,Rosinol Laura,Krishnan Amrita Y.,Gahrton Gösta,Bruno Benedetto

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-0887-4.pdf

Reference32 articles.

1. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–8.

2. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031–7.

3. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103:4362–4.

4. Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. Graft-versus-myeloma effect. Lancet. 1996;348:346.

5. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Allogeneic stem cell transplantation in multiple myeloma: is there still a place?;Frontiers in Oncology;2024-06-04

3. CAR-T Therapy in Multiple Myeloma: Looking Beyond;Hemato;2024-05-31

4. Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma;American Journal of Clinical Oncology;2024-03-14

5. Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center Experience;Cancers;2023-12-07